Market Intelligence, Clinical Progress, and High-Purity Reagents for CNS and Metabolic Disorder Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TAAR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TAAR1 Recombinant Protein (Membrane Extract) High purity, Endotoxin <1EU/ug. Sequence Verified. |
View TAAR1 Products |
| Gene Delivery | TAAR1 Lentivirus Premade Particles Full-length ORF (NM_175054), CMV promoter, Puromycin selection. Sequence Verified. High Titer (>1×10⁸ TU/mL). |
View TAAR1 Products |
| Stable Cell Line | TAAR1 HEK293 Stable Cell Line Pre-validated cAMP response to Tyramine/β-PEA. Endotoxin <1EU/ug. Monoclonal population. |
View TAAR1 Products |
| Benchmark Ab | Anti-TAAR1 Monoclonal Antibody (Clone 1E3) Recombinant rabbit monoclonal for Flow Cytometry and ICC validation of expression levels. |
View TAAR1 Products |
| Validator | TAAR1 siRNA Set (3 unique sequences) For knockdown confirmation and assay specificity control. Sequence Verified. |
View TAAR1 Products |
| Related Target | TAAR2 Stable Cell Line Trace amine receptor 2 for subfamily selectivity screening (avoid off-target activation). |
View TAAR2 Products |
| Related Target | DRD2 Stable Cell Line Dopamine D2 receptor for comparative antipsychotic mechanism and safety profiling. |
View DRD2 Products |
| Related Target | HTR2A (5-HT2A) Expression Vector Serotonin receptor for comprehensive CNS panel profiling. |
View HTR2A Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation & Glycosylation Integrity | Lentivirus-transduced HEK293 cells preserve native post-translational modifications. Human TAAR1 (NP_778224) expressed with verified N-terminal glycosylation sites intact. |
| Orthosteric vs. Allosteric Mechanism Validation | Wild-Type and E108A mutant (orthosteric site disrupted) stable cell line pairs available for mechanism-of-action studies. |
| Subfamily Selectivity (TAAR1 vs. TAAR2/5/9) | Homolog panel of TAAR2 and TAAR5 stable cell lines with >95% sequence accuracy for counter-screening. |
| Cross-species Translation (Human/Cyno/Mouse) | Human, Cynomolgus monkey (Macaca fascicularis), and Mouse ortholog stable cell lines available for PK/PD bridging studies. |
| Pathway Bias Detection (Gs vs. β-arrestin) | Pre-validated cAMP GloSensor and PathHunter β-arrestin recruitment compatible cell lines. |
Live TAAR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (TAAR1 Agonists)
- ➤ Latest Resistance & Tolerance Research
- ➤ Recent Patent Filings (Sunovion, Reviva, Lundbeck)
Global Clinical Landscape & Future Outlook
The race for TAAR1 (Trace amine-associated receptor 1) therapeutics is fundamentally reshaping the treatment of schizophrenia and related neuropsychiatric disorders. Major players are focused on small molecule TAAR1 agonists as a novel, non-D2-blocking mechanism of action, aiming to provide antipsychotic efficacy without the severe motor and metabolic side effects of atypical antipsychotics. As Sunovion's ulotaront (SEP-363856) advances through Phase 3 for schizophrenia and Reviva's brilaroxazine targets broader neuropsychiatric indications, the field is validating TAAR1 as a druggable target devoid of extrapyramidal side effects. The next wave of R&D is targeting metabolic disorders (obesity, diabetes) and stimulant use disorder, requiring robust peripheral and CNS-penetrant assay models. As first-generation therapies advance, the next wave will target highly selective dual-agonists and optimized brain penetrance.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Sunovion (Takeda), Reviva Pharma, Roche | Schizophrenia, Depression | cAMP accumulation assay in stable cell lines (need high surface expression) |
| Dual Agonist (TAAR1/5-HT1A) | Otsuka | Psychosis | Receptor selectivity panels (Need comprehensive GPCR ORFs) |
| Positive Allosteric Modulator (PAM) | Lundbeck, Biogen | Cognitive Impairment | Allosteric binding site mapping (WT vs. Mutant comparison) |
| Biased Ligand | Academic Consortia | Psychosis (reduced tolerance) | β-arrestin vs. Gs pathway bias screening (need dual-pathway validated cells) |
| Metabolic Indications | Emerging Biotechs | Obesity, Type 2 Diabetes | Peripheral vs. CNS receptor activation assays (species cross-reactive panel) |
Key Genetic Variants and Assay Tools
Understanding functional genetic variants is critical for TAAR1 drug development. Known variants include:
- dbSNP rs8192618 (UniProt VAR_049445): A documented single nucleotide polymorphism with potential impact on receptor function.
- Reduced G(i) activation variant (UniProt VAR_049446): This mutation leads to reduced activation of G(i) G alpha proteins in response to agonist binding, which may affect signaling bias.
TarMart provides wild-type (WT) and mutant (e.g., E108A for orthosteric site disruption) stable cell line pairs to enable mechanism-of-action studies and variant characterization. These tools are essential for validating orthosteric vs. allosteric mechanisms and for screening biased ligands.